Clinical experience with tenoxicam: a review.

Area of Science:

• Pharmacology
• Rheumatology
• Clinical Medicine

Background:

• Tenoxicam is a non-steroidal anti-inflammatory agent (NSAID) with a prolonged elimination half-life.
• Previous research indicated potential efficacy in osteoarthrosis (OA) and rheumatoid arthritis (RA).

Purpose of the Study:

• To evaluate the efficacy and safety of tenoxicam across various rheumatic conditions.
• To compare tenoxicam's gastrointestinal blood loss profile with other NSAIDs.
• To assess tenoxicam's pharmacokinetic properties, including half-life and accumulation in the elderly.

Main Methods:

• Nine clinical studies were conducted over five years.
• Comparative efficacy studies against naproxen (OA) and ibuprofen (RA).
• Faecal blood loss studies and pharmacokinetic assessments, including elderly populations.

Main Results:

• Tenoxicam showed efficacy in osteoarthrosis and rheumatoid arthritis.
• Gastrointestinal blood loss was lower than aspirin and comparable to piroxicam.
• Tenoxicam exhibited a long half-life in plasma (42 h) and synovial fluid (45 h).
• No progressive accumulation was observed in the elderly at steady state.

Conclusions:

• Tenoxicam is an efficacious NSAID for osteoarthrosis and rheumatoid arthritis.
• It presents a favorable gastrointestinal safety profile compared to aspirin.
• Pharmacokinetic studies confirm its long half-life and safe use in the elderly.